<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97467">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925157</url>
  </required_header>
  <id_info>
    <org_study_id>14848</org_study_id>
    <secondary_id>I6M-MC-SSAC</secondary_id>
    <nct_id>NCT01925157</nct_id>
  </id_info>
  <brief_title>A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)</brief_title>
  <official_title>A Single-Dose, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3090106 in Healthy Subjects and Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Moldova: National Ethics Committee</authority>
    <authority>Moldova: Medicines Agency</authority>
    <authority>Moldova: Ministry of Health</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Romania: Ethics Committee</authority>
    <authority>Bulgaria: Ethics committee</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Hungary: Research Ethics Medical Committee</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug known as
      LY3090106 in healthy participants and in participants with RA who are having an inadequate
      response to methotrexate (MTX).  The study will investigate how the body processes the study
      drug and how the study drug affects the body.  The study will last about 3 months for each
      participant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3090106</measure>
    <time_frame>Predose through 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-LY3090106 Antibodies</measure>
    <time_frame>Baseline through 12 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3090106</measure>
    <time_frame>Predose through 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>LY3090106 (Healthy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Healthy)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants will receive a single dose of placebo matching LY3090106 SQ.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3090106 (RA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (RA)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with RA will receive a single dose of placebo matching LY3090106 SQ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3090106 - SQ</intervention_name>
    <description>Administered SQ.</description>
    <arm_group_label>LY3090106 (Healthy)</arm_group_label>
    <arm_group_label>LY3090106 (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3090106 - IV</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3090106 (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo - SQ</intervention_name>
    <description>Administered SQ.</description>
    <arm_group_label>Placebo (Healthy)</arm_group_label>
    <arm_group_label>Placebo (RA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Healthy Participants:

          -  Males or non-pregnant females age 18 to 65 years

          -  Body Mass Index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m^2)

        Inclusion Criteria for Participants for RA:

          -  Diagnosis of at least mildly active adult-onset RA

          -  Positive anti-citrullinated protein (ACPA) antibodies or rheumatoid factor

          -  Regular use of MTX for at least 12 weeks and at a stable dose (10 to 25    mg/week)
             for at least 4 weeks prior to baseline

          -  American College of Rheumatology (ACR) Functional Class I, II or III

        Exclusion Criteria for Healthy Participants:

          -  Have received biologic agents within 3 months or 5 half-lives

          -  Have surgery within 12 weeks prior to screening

          -  Known history of human immunodeficiency virus (HIV infection and/or positive human
             HIV antibodies)

          -  Have evidence of, or test positive for, hepatitis C virus or hepatitis B virus

          -  Have evidence of active infection or fever

          -  Have donated greater than 500 mL blood within 30 days prior to screening

          -  Smoke greater than 10 cigarettes/day or equivalent

          -  Have received live vaccine within 1 month of screening

          -  Have a history of allergy to monoclonal antibodies or severe drug allergies

        Exclusion Criteria for Participants with RA:

          -  Have received prior or current treatment with biologic RA therapies

          -  Have received a live vaccine 28 days prior to screening or intend to receive a live
             vaccine during the course of the study

          -  Hemoglobin &lt; 10 grams per deciliter (g/dL), platelet count &lt; 100,000 cells/microliter
             (uL), total white blood cell count &lt; 3000 cells/uL, neutrophil count &lt; 2000 cells/uL,
             or lymphocyte count &lt; 500 cells/uL

          -  Aspartate transaminase (AST) &gt; 1.5 x upper limit or the normal range (ULN), alanine
             transamine (ALT) &gt; 1.5 x ULN, creatinine &gt; 1.5 mg/dL (114 micromoles/liter [uMol/L])

          -  Treatment with &gt; 10 mg/day or unstable dose of oral prednisone or equivalent within
             28 days of baseline

          -  Have required an increase in dose or a new prescription of narcotic  within 28 days
             prior to randomization

          -  Have received any parenteral corticosteroids within 28 days before screening

          -  Treatment with any oral disease-modifying anti-rheumatic drugs (DMARDs) other than
             MTX within 4 weeks prior to baseline

          -  Any neurological, psychiatric, vascular, or system disorder that could also affect
             the evaluation of disease activity assessments.  Anemia of chronic disease is allowed
             if hemoglobin &gt; 10 g/dL

          -  Have rheumatic or systemic autoimmune disease other than RA or significant active
             systemic involvement secondary to RA.  Participants with secondary Sjogren's syndrome
             are eligible.

          -  Uncontrolled arterial hypertension characterized by a confirmed systolic blood
             pressure of &gt; 150 mm Hg or diastolic blood pressure &gt; 90 mm Hg at screening or on day
             of study drug dosing

          -  Poorly controlled diabetes as defined by glycosylated hemoglobin (HbA1c) &gt; 8.0% at
             screening

          -  Known history of human immunodeficiency virus (HIV infection and/or positive human
             HIV antibodies)

          -  Have evidence of, or test positive for, hepatitis C virus or hepatitis B virus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLilly (1-877-285-4459) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559 or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Balatonf√ºred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>50159</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
